Edelman noted that for non-small-cell lung cancer -- that is, most lung cancers -- that has mutations in the gene,"[the researchers] think this should be the front-line therapy. And that is a very important conclusion that could change medical practice, because up until recently cancer therapy was just taking a elephant gun and just hoping you kill just the cancer and not the elephant. This is different. This is honing in on a specific receptor." 德曼指出，为非小细胞肺癌—也就是大多数肺癌—具有突变的基因， [研究者]认为这应该是前线的治疗。这是一个非常重要的结论，能改变医疗实践。因为直到最近癌症治疗只考虑拿着一把“大象枪”但只希望杀死只是癌症而不是大象。但现在不同了，现在只是针对特定的受体。
"The effect here is more dramatic than we usually see in cancer chemotherapy studies," Edelman added. "[The researchers] significantly delayed the onset of new disease, they significantly increased disease free-progression, and they clearly show that this new medication was more effective than the controlled medication." 德曼还说：在这里的影响是更为明显，不是我们通常在癌症化疗研究中看到， [研究者] 这种疗法大大推迟新的疾病发病、大大减少疾病进展，并且清楚地显示这种新的药物是比受管制药物更有效。
"And what's good about this is that it was a real-life study," he said. "They didn't compare the medication to placebo. They compared it to standard chemotherapy, which is a much more rigorous test of its usefulness and its efficacy." "它的好处就是它是对现实生活的研究“，他说。他们不拿它去跟安慰剂药物比较，他们把他和标准化疗去比较，这是一个更严格的测试，测试其作用和效果"。
易瑞沙、特罗凯、格列卫，
印度抗癌药邮购中心版权所有
。官方网址：www.india-anticancer.com
|
